title: Modulation of macrophage mannose receptor affects the uptake of virulent and avirulent Leishmania donovani promastigotes.
abstract: The effect of oxidants and the anti-inflammatory steroid dexamethasone on the attachment and internalization of virulent and avirulent Leishmania donovani promastigotes by the macrophage mannosyl fucosyl receptor was examined. Oxidants and dexamethasone are known to down- and upregulate the expression of the mannose receptor. Macrophages, when treated with 500 microM H2O2 at 37 C for 30 min, stimulate about 45% inhibition in uptake of an avirulent strain (UR6), and 30 and 25% inhibition for virulent strains AG-83 and GE-I, respectively. Treatment of macrophages with dexamethasone for 20 hr resulted in a stimulation in uptake of the parasite. When UR6 was used, a 3-fold increase in uptake was observed compared with the controls. Parasite uptake was also inhibited by the H2O2-generating system, glucose/glucose oxidase; inhibition was blocked by catalase. Treatment of macrophages either with H2O2 or dexamethasone did not affect the binding of the advanced glycosylation end product-bovine serum albumin (AGE-BSA), the ligand for AGE receptor of macrophages. Similarly, indirect evidence also shows that both types 1 and 3 complement receptors (CR1, CR3) are not affected by these treatments, indicating that, besides the mannosyl fucosyl receptor, other receptors are minimally altered in the identified condition. These results suggest that the up- and downregulation of the mannose receptor of macrophages may play a role in affecting L. donovani infection.
authors.affiliation: Biomembrane Division, Indian Institute of Chemical Biology, Calcutta.
authors.forename: P
authors.initials: P
authors.lastname: Chakraborty
authors.forename: D
authors.initials: D
authors.lastname: Ghosh
authors.forename: M K
authors.initials: MK
authors.lastname: Basu
mesh_terms: D000818:Animals; D000893:Anti-Inflammatory Agents / Q000494:pharmacology*; D001667:Binding, Competitive; D002374:Catalase / Q000494:pharmacology; D003907:Dexamethasone / Q000494:pharmacology*; D005260:Female; D017127:Glycation End Products, Advanced / Q000276:immunology; D006861:Hydrogen Peroxide / Q000494:pharmacology*; D037181:Lectins, C-Type; D007893:Leishmania donovani / Q000276:immunology / Q000378:metabolism* / Q000472:pathogenicity; D017737:Macrophages, Peritoneal / Q000276:immunology / Q000378:metabolism / Q000469:parasitology*; D000090323:Mannose Receptor; D037241:Mannose-Binding Lectins; D051379:Mice; D008807:Mice, Inbred BALB C; D016877:Oxidants / Q000494:pharmacology*; D010587:Phagocytosis / Q000187:drug effects; D011956:Receptors, Cell Surface / Q000032:analysis / Q000096:biosynthesis* / Q000276:immunology
chemical_list: D000893:Anti-Inflammatory Agents; D017127:Glycation End Products, Advanced; D037181:Lectins, C-Type; D000090323:Mannose Receptor; D037241:Mannose-Binding Lectins; D016877:Oxidants; D011956:Receptors, Cell Surface; D003907:Dexamethasone; D006861:Hydrogen Peroxide; D002374:Catalase